City of Hope | Strategic Alliance Partners

March 31, 2023

In this sixth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, share efforts to increase awareness around endoscopy in gastrointestinal cancer.

March 29, 2023

In this fifth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, review the potential role for endoscopic ablation in gastrointestinal cancer.

March 28, 2023

The evaluation of diagnostic quality in precision medicine should almost certainly be assessed by standards different from those used in drug development.

March 24, 2023

In this fourth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, provide insight on the use of endoscopic submucosal resection and endoscopic evaluation for tumor response as it pertains to organ preservation in gastrointestinal cancer.

March 22, 2023

In this third episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, highlight the advantages and scope of endoscopic procedures in gastrointestinal cancer.

March 17, 2023

In this second episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, explain the evolution of minimally invasive surgery and the emergence of interventional radiology in gastrointestinal cancer.

March 16, 2023

As the great baseball catcher and philosopher Yogi Berra noted, “When you come to a fork in the road, take it.” And in my opinion, we surely are at that juncture with human papillomavirus vaccination.

March 15, 2023

In this first episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, discuss the importance of endoscopic oncology as it relates to rising cancer incidence and multidisciplinary care in gastrointestinal cancer.

March 10, 2023

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.

March 09, 2023

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of the CDK9 inhibitor KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.

March 02, 2023

Phase 3 randomized trials often fail to reasonably represent the actual population of patients seen in routine community practice.

February 28, 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

February 24, 2023

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

February 21, 2023

Successful manipulation of the immune system to achieve regression of cancer, long an unfulfilled goal of oncologic investigation, is an ever-increasing reality in multiple clinical settings.

February 21, 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

February 21, 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

February 14, 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

February 14, 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

February 13, 2023

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

February 08, 2023

Despite the favorable comments and interest in clinical trials, the objective fact is that a distressingly low percentage of patients with cancer, in the range of 2% to 4%, are enrolled in clinical investigative efforts.